kidney transplantation/ niertransplantatie rejection/ rejectie alloreactivity/ alloreactiviteit lymph nodes/ lymfklieren
Conditions
Interventions
80 patients in group 1 (ABO-compatible)
20 patients in group 2 (ABO-incompatible)
Sponsors
Erasmus Medical Center
Eligibility
Inclusion criteria
Inclusion criteria: In order to be eligible to participate in this study, a subject must meet the following criteria: - Adult patients receiving a deceased or living kidney transplant in the Erasmus Medical Center Rotterdam, The Netherlands and: - Group 1: o Historical PRA > 6% and/ or: o HLA MM ¡Ý4 on A, B and DR loci - Group 2: o Recipients of an ABO-incompatible kidney graft. Patients have to give written informed consent to participate in the study.
Exclusion criteria
Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: - ABO-compatible HLA identical living-related transplant recipients. - Patients unable to give written informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| -The primary objective for this study is to determine the prognostic characteristics for BPAR in the first 3 months after transplantation, as assessed in the lymphocyte composition of the lymph node in immunologically high-risk kidney transplantation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary objectives of the study: - to capture global composition of lymph node versus blood leukocyte subsets in renal insufficiency[20]. - to compare the immunological ageing profile of T cells in the peripheral blood to the T cells derived from the lymph node. - to assess whether pre-transplant frequencies of lymph node derived TFH, T and B cells predict BPAR. - to assess differences in lymphocyte composition of lymph nodes in alemtuzumab treated versus untreated patients both in single cell suspension and within the tissue [21, 22]. (ABO-incompatible kidney transplant recipients receive alemtuzumab induction therapy three weeks before transplantation). This study will result in a set of defined markers that will identify patients at risk to develop rejection. | — |
Contacts
Public ContactA.E. Weerd, de
Internist-nephrologist Erasmus Medical Center Room D-411 Postbus 2040
Outcome results
None listed